Abstract
For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and Omalizumab. A novel intranasal formulation of azelastine and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines.
Original language | English |
---|---|
Pages (from-to) | 705-714 |
Number of pages | 10 |
Journal | Expert Review of Clinical Pharmacology |
Volume | 9 |
Issue number | 5 |
Early online date | 27 Feb 2016 |
DOIs | |
Publication status | Published - 2016 |
Keywords
- allergic rhinitis
- effectiveness
- MP-AzeFlu
- real-life